Sakakibara Shan Riku sold $880K of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 8,000 shares of BillionToOne, Inc. (BLLN) at $110.00 ($0.88M total) across 2 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Jun 26, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (8,000 shares at $110/share) but does not introduce new operating or financial information.

02

Market read

Traders may treat this as a minor sentiment input rather than a fundamental catalyst due to the 10b5-1 structure.

03

What to watch

The filing doesn’t disclose new fundamentals (no guidance, trial, or deal). The only actionable element is monitoring for additional insider transactions or corroborating catalysts.

Relevance 4/10Novelty 4/10Timing: filed after-hours on 2026-06-26; reflects trades dated 2026-06-24

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

SEC Form 4 shows BLLN CPO Sakakibara Shan Riku sold 8,000 shares at $110/share under a 10b5-1 plan, totaling $880k.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale, which reduces interpretive weight versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical and not a bearish signal; traders may ignore it absent follow-on news.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale by its Chief Product Officer.

  • Sakakibara Shan Riku

    Chief Product Officer who sold 8,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.